Abbisko Forms $258 Million Collaboration with Lilly for Cardiometabolic Candidates
January 18, 2022 at 05:48 AM EST
Abbisko Therapeutics of Shanghai formed a global collaboration worth up to $258 million with Lilly to continue discovery and development of novel molecules for cardiometabolic diseases. Abbisko will be responsible for further discovery/development of molecules that modulate a novel target using its proprietary R&D platform. If Abbisko successfully advances the compounds to their endpoints, Lilly will have the right to take over commercialization. If Lilly elects not to advance the compounds, Abbisko will have global rights to the candidate and pay milestones and royalties to Lilly. More details.... Stock Symbols: (HK: 2256) (NYSE: LLY) Share this with colleagues: // //
